In a report released yesterday, Martin Auster from Credit Suisse maintained a Hold rating on Ultragenyx Pharmaceutical (RARE – Research Report), with a price target of $64.00. The company’s shares closed last Friday at $77.98. According to TipRanks.com, Auster is